BR112017002183A2 - conjugado, composição farmacêutica, e, método para aumentar uma resposta imune em um mamífero - Google Patents
conjugado, composição farmacêutica, e, método para aumentar uma resposta imune em um mamíferoInfo
- Publication number
- BR112017002183A2 BR112017002183A2 BR112017002183-8A BR112017002183A BR112017002183A2 BR 112017002183 A2 BR112017002183 A2 BR 112017002183A2 BR 112017002183 A BR112017002183 A BR 112017002183A BR 112017002183 A2 BR112017002183 A2 BR 112017002183A2
- Authority
- BR
- Brazil
- Prior art keywords
- conjugate
- mammal
- enhancing
- immune response
- pharmaceutical composition
- Prior art date
Links
- 241000124008 Mammalia Species 0.000 title abstract 3
- 230000002708 enhancing effect Effects 0.000 title abstract 2
- 230000028993 immune response Effects 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000000427 antigen Substances 0.000 abstract 4
- 102000036639 antigens Human genes 0.000 abstract 4
- 108091007433 antigens Proteins 0.000 abstract 4
- 101150078778 SPB1 gene Proteins 0.000 abstract 2
- 241000193985 Streptococcus agalactiae Species 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6068—Other bacterial proteins, e.g. OMP
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14179945 | 2014-08-05 | ||
| EP14179945.2 | 2014-08-05 | ||
| PCT/EP2015/068012 WO2016020413A1 (en) | 2014-08-05 | 2015-08-05 | Carrier molecule for antigens |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112017002183A2 true BR112017002183A2 (pt) | 2018-01-16 |
Family
ID=51298571
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112017002183-8A BR112017002183A2 (pt) | 2014-08-05 | 2015-08-05 | conjugado, composição farmacêutica, e, método para aumentar uma resposta imune em um mamífero |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US10245310B2 (enExample) |
| EP (1) | EP3177324A1 (enExample) |
| JP (1) | JP2017523985A (enExample) |
| KR (1) | KR20170039709A (enExample) |
| CN (1) | CN108064174A (enExample) |
| AR (1) | AR101455A1 (enExample) |
| AU (1) | AU2015299008B2 (enExample) |
| BE (1) | BE1022792B1 (enExample) |
| BR (1) | BR112017002183A2 (enExample) |
| CA (1) | CA2957118A1 (enExample) |
| EA (1) | EA201790239A1 (enExample) |
| IL (1) | IL250238A0 (enExample) |
| MX (1) | MX2017001638A (enExample) |
| SG (1) | SG11201700673RA (enExample) |
| WO (1) | WO2016020413A1 (enExample) |
| ZA (1) | ZA201700824B (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008543907A (ja) * | 2005-06-27 | 2008-12-04 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 免疫原性組成物 |
| EP3551668A1 (en) | 2016-12-06 | 2019-10-16 | GlaxoSmithKline Biologicals S.A. | Purification process for capsular polysaccharide |
| US11951165B2 (en) | 2016-12-30 | 2024-04-09 | Vaxcyte, Inc. | Conjugated vaccine carrier proteins |
| WO2018126229A2 (en) | 2016-12-30 | 2018-07-05 | Sutrovax, Inc. | Polypeptide-antigen conjugates with non-natural amino acids |
| CA3057715A1 (en) * | 2017-04-04 | 2018-10-11 | Avidea Technologies, Inc. | Peptide-based vaccines, methods of manufacturing, and uses thereof for inducing an immune response |
| CA3066020A1 (en) | 2017-06-16 | 2018-12-20 | Glaxosmithkline Biologicals Sa | Method of treatment |
| WO2019217665A1 (en) * | 2018-05-09 | 2019-11-14 | West Virginia University | Iron-acquisition receptor peptide administration for vaccination against pseudomonas aeruginosa |
| EP3574915A1 (en) * | 2018-05-29 | 2019-12-04 | Neovacs | Immunogenic product comprising il-4 and/or il-13 for treating disorders associated with aberrant il-4 and/or il 13 expression or activity |
| ES2989087T3 (es) * | 2018-07-04 | 2024-11-25 | Vaxcyte Inc | Mejoras en conjugados inmunogénicos |
| WO2020010000A1 (en) * | 2018-07-04 | 2020-01-09 | Sutrovax, Inc. | Improved methods for the preparation of immunogenic conjugates |
| CN108840914B (zh) * | 2018-08-13 | 2022-07-01 | 内蒙古民族大学 | 一种具有免疫原性的多肽、其抗体的制备方法以及用途 |
| AU2020253332A1 (en) * | 2019-04-02 | 2021-11-25 | Vaxcyte, Inc. | Optimized cell-free synthesis of Invasion Plasmid Antigen B and related compositions and methods of use |
| US20220387614A1 (en) | 2019-11-22 | 2022-12-08 | Glaxosmithkline Biologicals Sa | Dosage and administration of a bacterial saccharide glycoconjugate vaccine |
| EP4165064A2 (en) * | 2020-06-12 | 2023-04-19 | GlaxoSmithKline Biologicals S.A. | Dock tag system |
| WO2021250625A2 (en) | 2020-06-12 | 2021-12-16 | Glaxosmithkline Biologicals Sa | Gbs ferritin nanoparticles |
| CN112979797B (zh) * | 2021-04-28 | 2022-04-01 | 中国检验检疫科学研究院 | 一种抗赤羽病病毒单克隆抗体及其制备方法与应用 |
| GB202215634D0 (en) * | 2022-10-21 | 2022-12-07 | Glaxosmithkline Biologicals Sa | Polypeptide scaffold |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006078318A2 (en) * | 2004-07-29 | 2006-07-27 | Novartis Vaccines And Diagnostics Inc. | Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae |
| JP2008525033A (ja) | 2004-12-22 | 2008-07-17 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド | Ｂ群連鎖球菌 |
| GB0502095D0 (en) * | 2005-02-01 | 2005-03-09 | Chiron Srl | Conjugation of streptococcal capsular saccharides |
| GB0605757D0 (en) * | 2006-03-22 | 2006-05-03 | Chiron Srl | Separation of conjugated and unconjugated components |
| EP2063911A2 (en) * | 2006-07-26 | 2009-06-03 | Novartis Ag | Immunogenic compositions for gram positive bacteria |
| GB0802503D0 (en) * | 2008-02-11 | 2008-03-19 | Novartis Ag | Hybrid polypeptide |
| WO2010079464A1 (en) | 2009-01-12 | 2010-07-15 | Novartis Ag | Cna_b domain antigens in vaccines against gram positive bacteria |
| GB201003333D0 (en) | 2010-02-26 | 2010-04-14 | Novartis Ag | Immunogenic proteins and compositions |
| GB201005625D0 (en) * | 2010-04-01 | 2010-05-19 | Novartis Ag | Immunogenic proteins and compositions |
| GB201114923D0 (en) | 2011-08-30 | 2011-10-12 | Novartis Ag | Immunogenic proteins and compositions |
| AU2013224026A1 (en) | 2012-02-24 | 2014-08-21 | Novartis Ag | Pilus proteins and compositions |
-
2015
- 2015-08-05 SG SG11201700673RA patent/SG11201700673RA/en unknown
- 2015-08-05 US US15/501,474 patent/US10245310B2/en active Active
- 2015-08-05 AU AU2015299008A patent/AU2015299008B2/en not_active Expired - Fee Related
- 2015-08-05 BR BR112017002183-8A patent/BR112017002183A2/pt not_active IP Right Cessation
- 2015-08-05 MX MX2017001638A patent/MX2017001638A/es unknown
- 2015-08-05 CA CA2957118A patent/CA2957118A1/en not_active Abandoned
- 2015-08-05 WO PCT/EP2015/068012 patent/WO2016020413A1/en not_active Ceased
- 2015-08-05 JP JP2017506294A patent/JP2017523985A/ja active Pending
- 2015-08-05 AR ARP150102512A patent/AR101455A1/es unknown
- 2015-08-05 BE BE2015/5496A patent/BE1022792B1/fr not_active IP Right Cessation
- 2015-08-05 EP EP15744610.5A patent/EP3177324A1/en not_active Withdrawn
- 2015-08-05 CN CN201580053997.XA patent/CN108064174A/zh active Pending
- 2015-08-05 EA EA201790239A patent/EA201790239A1/ru unknown
- 2015-08-05 KR KR1020177005840A patent/KR20170039709A/ko not_active Withdrawn
-
2017
- 2017-01-23 IL IL250238A patent/IL250238A0/en unknown
- 2017-02-02 ZA ZA2017/00824A patent/ZA201700824B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US10245310B2 (en) | 2019-04-02 |
| WO2016020413A1 (en) | 2016-02-11 |
| CN108064174A (zh) | 2018-05-22 |
| US20170224803A1 (en) | 2017-08-10 |
| MX2017001638A (es) | 2017-04-27 |
| AU2015299008A1 (en) | 2017-02-23 |
| JP2017523985A (ja) | 2017-08-24 |
| IL250238A0 (en) | 2017-03-30 |
| SG11201700673RA (en) | 2017-02-27 |
| AR101455A1 (es) | 2016-12-21 |
| KR20170039709A (ko) | 2017-04-11 |
| AU2015299008B2 (en) | 2018-08-02 |
| CA2957118A1 (en) | 2016-02-11 |
| BE1022792B1 (fr) | 2016-09-06 |
| EA201790239A1 (ru) | 2017-07-31 |
| BE1022792A1 (fr) | 2016-09-06 |
| EP3177324A1 (en) | 2017-06-14 |
| ZA201700824B (en) | 2019-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112017002183A2 (pt) | conjugado, composição farmacêutica, e, método para aumentar uma resposta imune em um mamífero | |
| IL270714A (en) | Liver organoid compositions and methods of making and using same | |
| BR112018010085A2 (pt) | ligantes de pd1/ctla4 | |
| MX381232B (es) | Formulación de anticuerpos. | |
| BR112015030229A8 (pt) | Partícula semelhante a vírus compreendendo um polipeptídeo e um antígeno da malária, vetor, composições farmacêutica e de vacina, bem como molécula de ácido nucleico isolado | |
| CL2016000468A1 (es) | Conjugados anti-dll3 (ligando3 tipo delta) manipulados y métodos de uso. | |
| CL2016000465A1 (es) | Métodos de conjugación de anticuerpos específicos de sitio y composiciones. | |
| IL275798A (en) | Methods for antibody drug conjugation, purification and formulation | |
| BR112018001572A2 (pt) | método para induzir uma resposta imune, antígeno, adenovírus, uso de um antígeno e de um adenovírus, e, polinucleotídeo. | |
| AR093377A1 (es) | Anticuerpos anti-notch y conjugados de anticuerpo-farmaco | |
| CU20160101A7 (es) | Inmunoglobulina con fab en tándem | |
| CR20200409A (es) | Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la misma terapia contra el cáncer epitelial de ovario y otros tipos de cáncer (divisional 2018-0027). | |
| BR112016008576A2 (pt) | Formulações aquosas estáveis de anticorpos e forma farmacêutica de dosagem unitária | |
| TN2015000402A1 (fr) | Methods for treating crohn's disease using an anti-il23 antibody | |
| BR112016014284A2 (pt) | anticorpo caninizado isolado ou um fragmento de ligação de antígeno do mesmo, ácido nucleico isolado, vetor de expressão, célula hospedeira, composição farmacêutica, e, métodos para aumentar a atividade de uma célula imune e para produzir um anticorpo caninizado ou fragmento de ligação de antígeno do mesmo | |
| CR20170419A (es) | Nuevos péptidos y nueva combinación de péptidos para el uso en la inmunoterapia contra el cáncer de páncreas y otros tipos de cáncer. | |
| AU2018253589A1 (en) | Antibodies, pharmaceutical compositions and uses thereof | |
| BR112016020112A2 (pt) | anticorpos multiespecíficos, método para a preparação de um anticorpo multiespecífico, ácido nucleico, vetor de expressão e composição farmacêutica | |
| MX2014005372A (es) | Molecula portadora que comprende un antigeno spr0096 y un spr2021. | |
| MX362456B (es) | Anticuerpos y vacunas para utilizarse en el tratamiento de canceres por ror1 y para inhibir la metastasis. | |
| MX421186B (es) | Constructos de anticuerpos. | |
| MX2018015272A (es) | Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco. | |
| MX2018015268A (es) | Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco. | |
| CY1117214T1 (el) | Συνθεση για ελεγχομενη διεγερση των ωοθηκων | |
| MX2018015274A (es) | Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B15K | Others concerning applications: alteration of classification |
Ipc: A61K 47/00 (2006.01), A61P 37/04 (2006.01) |
|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A ANUIDADE. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2595 DE 29-09-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |